SLRX Salarius Pharmaceuticals, Inc.: חובות לטווח קצר של החברה

Salarius Pharmaceuticals (SLRX) develops advanced genetic therapies to combat severe oncological pathologies across various age groups. This chart of stock quotes complements the business data, where the indicator stands at 0.00. Patent protection minimizes price wars, leaving risks solely to the scientific discoveries of competitors. However, a critical liquidity shortage and previous FDA regulatory delays pose a threat of company closure.

Salarius Pharmaceuticals focuses on developing precision epigenetic drugs to combat rare sarcomas and pediatric oncology. The dynamics of short-term liabilities reflect the total obligations maturing within one year, allowing investors to assess current liquidity and the risk of capital shortages when funding costly clinical trials, independent of market noise.